Dupilumab lowers nighttime symptoms, exacerbation rate in type 2 asthma

Patients with moderate to severe type 2 asthma, poor asthma control and high sleep disturbance experienced fewer nighttime symptoms and exacerbations with dupilumab, according to results published in Respiratory Medicine.
“This post-hoc analysis … showed that dupilumab treatment significantly reduced nighttime symptoms, exacerbations, and [short-acting beta agonist] use, and improved lung function, asthma control, and health-related [quality of life],” Jorge F. Maspero, MD, FCCP, FAAAAI, director for allergy and respiratory medicine at Fundación Cidea, and colleagues

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart